OCUGEN INC (OCGN) Stock Price, Forecast & Analysis
NASDAQ:OCGN • US67577C1053
OCGN Key Statistics, Chart & Performance
The current stock price of OCGN is 1.59 USD. In the past month the price increased by 6.71%. In the past year, price increased by 133.82%.
OCGN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to OCGN. When comparing the yearly performance of all stocks, OCGN is one of the better performing stocks in the market, outperforming 95.82% of all stocks.
OCGN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OCGN. OCGN may be in some trouble as it scores bad on both profitability and health.
OCGN Financial Highlights
Over the last trailing twelve months OCGN reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS decreased by -29.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -111.15% | ||
| ROE | -1812.06% | ||
| Debt/Equity | 8.04 |
OCGN Forecast & Estimates
11 analysts have analysed OCGN and the average price target is 9.18 USD. This implies a price increase of 477.36% is expected in the next year compared to the current price of 1.59.
For the next year, analysts expect an EPS growth of -19.18% and a revenue growth 49.2% for OCGN
OCGN Ownership
OCGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.45 | 404.235B | ||
| AMGN | AMGEN INC | 16.66 | 204.477B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 189.501B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 119.327B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.84 | 83.747B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.66 | 43.95B | ||
| INSM | INSMED INC | N/A | 32.227B | ||
| NTRA | NATERA INC | N/A | 29.989B | ||
| BIIB | BIOGEN INC | 12.63 | 28.491B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.499B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OCGN
Company Profile
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 95 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Company Info
OCUGEN INC
11 Great Valley Parkway
Malvern PENNSYLVANIA 19355 US
CEO: Shankar Musunuri
Employees: 95
Phone: 13026587581
OCUGEN INC / OCGN FAQ
What does OCGN do?
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. The company is headquartered in Malvern, Pennsylvania and currently employs 95 full-time employees. The company went IPO on 2014-12-03. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. The company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. The company is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
What is the current price of OCGN stock?
The current stock price of OCGN is 1.59 USD. The price increased by 7.43% in the last trading session.
Does OCGN stock pay dividends?
OCGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of OCGN stock?
OCGN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is OCUGEN INC (OCGN) stock traded?
OCGN stock is listed on the Nasdaq exchange.
What sector and industry does OCUGEN INC belong to?
OCUGEN INC (OCGN) operates in the Health Care sector and the Biotechnology industry.
Who owns OCUGEN INC?
You can find the ownership structure of OCUGEN INC (OCGN) on the Ownership tab.